Tenumomeran/raplemomeran plus pembrolizumab missed the PFS end point in HPV16-positive HNSCC.
Related to this article
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer
2
Dr Berdeja on the Potential Role of CELMoDs in Multiple Myeloma Management
3
Dr Goetz on the Navigation of Oral SERDs and Targeted Therapy in Advanced Breast Cancer
4
The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer
5